To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson’s disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
DAT-Flp Mouse*
Mouse Model
DAT-FlpO knock-in mice express optimized Flp recombinase (FlpO) from the mouse Slc6a3 (DAT) promoter in Slc6a3-expressing cells, including dopaminergic neurons. Model was generated and deposited by Dr. Rui Costa at Allen Institute through the MJFF Sponsored Tools Program, and supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Rab21 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in Rab21, including
- -S71R (heterozygous and homozygous) - in development, estimated late 2026
- -Knockout (homozygous) - in development, estimated late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
RAB32 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in RAB32, including
- -S71R (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
SLC18B1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SLC18B1, including
- S30P (heterozygous and homozygous) - in development, est late 2026
- Knockout (homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
PPM1M Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PPM1M, including
- -D440N (heterozygous and homozygous) - in development, est late 2026
- -Knockout (homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
TRPM2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including
- rs56379273 (heterozygous and homozygous) - in development, est late 2026
- Knockout (homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Parkin Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PRKN, including
- -R42P (heterozygous and homozygous)
- -T240M (heterozygous and homozygous)
- -R275W (heterozygous and homozygous)
- -P437L (heterozygous and homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
GRN Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including
- -A9D (heterozygous and homozygous) - in development, est late 2025
- -Q125X (heterozygous and homozygous)
- -R493X (heterozygous and homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
TMEM192 Antibody (Hu)
Antibody
Rabbit monoclonal antibody directed against human TMEM192 for immunoprecipitation of lysosomes. A version of this antibody conjugated to magnetic beads is also available. This antibody was generated by Dr. Dario Alessi at the University of Dundee and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
TMEM192 Antibody (Ms)
Antibody
Rabbit monoclonal antibody directed against mouse TMEM192 for immunoprecipitation of lysosomes. A version of this antibody conjugated to magnetic beads is also available. This antibody was generated by Dr. Dario Alessi at the University of Dundee and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
Have questions or need additional information?
Email [email protected] with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic